Synlogic is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of synthetic biotic. Co.'s pipeline includes: SYNB1934, which is an orally administered, non-systemically absorbed drug candidate based on a genetically engineered form of the probiotic E. coli Nissle; SYNB1353, which is a drug candidate designed to consume methionine, in the gastrointestinal (GI) tract thereby lowering homocysteine levels in patients with homocystinuria; SYNB8802, which is being developed for the treatment of enteric hyperoxaluria, a chronic, progressive disease; and SYNB2081, which is a synthetic biotic designed to consume uric acid in the GI tract. The SYBX YTD return is shown above.
The YTD Return on the SYBX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SYBX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SYBX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|